CLINICAL CASE OF A PATIENT WITH EXTREME HYPERTROPHIC CARDIOMYOPATHY AND RECURRENT IDIOPATHIC TRANSUDATIVE PERICARDIAL EFFUSION
Elena V. Dren’,
Nerses K. Sogoyan,
Irina N. Lyapina,
Daria P. Golubovskaya,
Tamara B. Pecherina,
Olga L. Barbarash https://doi.org/10.17802/2306-1278-2023-12-3-126-135
Abstract
Highlights
We report a case of a patient with extreme hypertrophic cardiomyopathy and complex cardiac pathology undergoing heart transplantation. The article will be useful for cardiologists, therapists and cardiovascular surgeons.
Abstract
We present a case of a patient with extreme hypertrophic cardiomyopathy, Wolff–Parkinson–White syndrome and nonspecific chronic exudative pericardial effusion with recurrent idiopathic transudative pericardial effusion. This case involves several approaches to treatment – medication and surgery for treating a patient with combined cardiomyopathy and pericardial effusion, which served as a “bridge” for a later change inro radical treatment - orthotopic heart transplantation.
About the Authors
Elena V. Dren’
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
Postgraduate student, Laboratory Assistant at the Laboratory of Myocardial Fibrogenesis, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Nerses K. Sogoyan
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
Postgraduate student, Cardiovascular Surgeon at the Department of Cardiac Surgery No. 1, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Irina N. Lyapina
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
PhD, Senior Researcher at the Laboratory of Rehabilitation, Department of Clinical Cardiology, Cardiologist at the Pulmonary Arterial Hypertension Center, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Daria P. Golubovskaya
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
Junior Researcher at the Laboratory of Myocardial Fibrogenesis, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Tamara B. Pecherina
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
PhD, Head of the Laboratory of Myocardial Fibrogenesis, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
Olga L. Barbarash
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”
Russian Federation
Russian Federation
PhD, Professor, Academician of the Russian Academy of Sciences, Director of the Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Kemerovo, Russian Federation
References
1. Russian Society of Cardiology, Clinical guidelines. Hypertrophic cardiomyopathy. 2020; (In Russian). Date of application 09.01.2023. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Kardiomiopatiya.
2. Elliott P.M., Anastasakis A., Borger M.A., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal. 2014;35(39):2733-2779. doi: 10.1093/eurheartj/ehu284.
3. Lancellotti P., Patricia A Pellikka., Budts W., Farooq A Chaudhry, Donal E., et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2017;30(2):101-138. doi: 10.1016/j.echo.2016.10.016.
4. Finocchiaro G. Magavern E., Sinagra G., Ashley E., Papadakis M., Tome-Esteban M., Sharma S., Olivotto I. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. Journal of the American Heart Association. 2017;6(12):1-11. doi: 10.1161/JAHA.117.007161.
5. Marian A.J., Braunwald E. Hypertrophic cardiomyopathy: Genetics,pathogenesis clinical manifestations, diagnosis, and therapy. Circulation Research. 2017; 121(7):749-770. doi: 10.1161/CIRCRESAHA.117.311059.
6. Puwanant, S., Kittipibul, V., Songsirisuk, N. et al. Idiopathic pericardial effusion in patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2022; 38(2):331-337. https://doi.org/10.1007/s10554-021-02424-8.
7. Kostareva A., Gudkova A., Sjöberg G., Mörner S., Semernin E., Krutikov A., Shlyakhto E., Sejersen T. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol. 2009; 131(3):410-412. doi: 10.1016/j.ijcard.2007.07.108.
8. Marrakchi S., Kammoun I., Bennour E., Laroussi L., Kachboura S. Risk stratification in hypertrophic cardiomyopathy. Herz. 2020; 45(1):50-64. doi: 10.1007/s00059-018-4700-8.
9. Abbas A.E., Fortuin F.D., Schiller N.B., et al. Echocardiographic determination of mean pulmonary artery. American Journal of Cardiology. 2003;92(11):1373–1376 doi: 10.1016/j.amjcard.2003.08.037.
10. Imazio M., Adler Y. Management of pericardial effusion. European Heart Journal. 2013; 34(16):1186-1197. doi: 10.1093/eurheartj/ehs372.
11. Puwanant S., Kittipibul V., Songsirisuk N., et al. Idiopathic pericardial effusion in patients with hypertrophic cardiomyopathy. The International Journal of Cardiovascular Imaging. 2022;38: 331–337. doi: 10.1007/s10554-021-02424-8.
12. Russian Transplant Society. Clinical guidelines. Heart transplantation and mechanical circulatory support. 2016:115 (In Russian). Date of application 10.01.2023.
13. Martinez H.R., Beasley G.S., Miller N., Goldberg J.F., Jefferies J.L. Clinical insights into heritable cardiomyopathies. Frontiers in Genetics. 2021; 12:1-16.Article 663450. doi:10.3389/fgene.2021.663450.
14. Maron B.J., Rowin E.J., Maron M.S. Global Burden of Hypertrophic Cardiomyopathy. JACC: Heart Failure. 2018;6(5):376-8. doi:10.1016/j.jchf.2018.03.004.
15. Adler Y., Charron P., Imazio M., Badano L., et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(44): 2921-2964. doi:10.1093/eurheartj/ehv319.
Supplementary files
Review
For citations:
Dren’ E.V., Sogoyan N.K., Lyapina I.N., Golubovskaya D.P., Pecherina T.B., Barbarash O.L. CLINICAL CASE OF A PATIENT WITH EXTREME HYPERTROPHIC CARDIOMYOPATHY AND RECURRENT IDIOPATHIC TRANSUDATIVE PERICARDIAL EFFUSION. Complex Issues of Cardiovascular Diseases. 2023;12(3):126-135. (In Russ.) https://doi.org/10.17802/2306-1278-2023-12-3-126-135
Views:
613
